Porta, C., Levy, A., Hawkins, R., Castellano, D., Bellmunt, J., Nathan, P., McDermott, R., Wagstaff, J., Donnellan, P., McCaffrey, J., Vekeman, F., Neary, M. P., Diaz, J., Mehmud, F., & Duh, M. S. (n.d.). impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first‐line sunitinib: a medical chart review across ten centers in five European countries. Cancer medicine, 3, 1517–1526. http://access.bl.uk/ark:/81055/vdc_100025009765.0x00001a